psma-617 and Bone-Neoplasms

177 Lu-prostate-specific membrane antigen (PSMA) for metastatic castration-resistant prostate cancer has emerged as a very promising therapy. However, some of the PSMA-expressing positive metastatic castration-resistant prostate cancer patients never respond or develop resistance to 177 Lu-PSMA. We present a case of castration-resistant prostate cancer with multiple bone metastases. Remission of clinical symptoms and imaging lesions can be observed after 4 cycles of 225 Ac-PSMA-617 therapy. Moreover, the man did not have any observable adverse effects.

Topics: Bone Neoplasms; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Treatment Outcome